Evaluating a combined therapy for patients recovering from post intensive care syndrome after ischemic stroke
Official title: Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN® Tablets, at 2-3 Stages of Rehabilitation of Patients With Post Intensive Care Syndrome
Run by POLYSAN Scientific & Technological Pharmaceutical Company · NCT06735898 · Data updated 2026-11-12
This study is testing a new combined therapy to help people recovering from post intensive care syndrome after an ischemic stroke feel better during their rehabilitation.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | POLYSAN Scientific & Technological Pharmaceutical Company Industry-sponsored |
| Locations | 1 site (Yekaterinburg, Sverdlovsk Oblast) |
| Status | Recruiting |
| Started | March 1, 2024 |
| Main results expected | December 1, 2025 |
| Study ends | May 1, 2026 |
| Registry record updated | April 6, 2025 |
| Trial ID | NCT06735898 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 who have been in intensive care for at least three days and have a diagnosis of moderate-to-severe post intensive care syndrome.
✕Probably not a fit
Patients with acute organ failures or those with a premorbid level of vital activity assessed as 4-5 points may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on patients who have experienced post intensive care syndrome (PIC syndrome) following an ischemic stroke. It aims to evaluate the efficacy of a combined therapy using CYTOFLAVIN® intravenous solution and tablets during the rehabilitation process. The approach emphasizes early rehabilitation interventions to address cognitive, motor, and emotional disorders that arise from prolonged intensive care. The study will include patients who have been in intensive care for at least three days and have moderate-to-severe PIC syndrome.
Why it matters
Potential benefit: If successful, this therapy could significantly improve recovery outcomes for patients suffering from post intensive care syndrome.
How similar studies have gone: While the specific combination therapy is novel, similar rehabilitation approaches have shown promise in improving outcomes for patients with post intensive care syndrome.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women over 18 years of age and older; * Stay in the ITU and (or) intensive care unit for at least 3 days; * Diagnosed "post intensive care" syndrome (PIC syndrome) with moderate-to-severe severity \>3\<6 points * Diagnosed modalities "critical illness polyneuropathy, respiratory neuropathy, dysphagia" of the domain "Neuromuscular complications" of PIC syndrome at 2-3 stages of the rehabilitation route at any value of PICS severity index * Diagnosed modalities "decreased gravitational gradient, decreased exercise tolerance" in the domain "Vegetative-metabolic complications" at 2-3 stages of the rehabilitation route at any value of PICS severity index Exclusion Criteria: * Premorbid level of vital activity when assessed on the rehabilitation routing scale 4-5 points; * Hematocrit ≤30%; * Hemoglobin level ≤80 g/L; * Acute cardiac failure; * Acute respiratory failure; * Acute renal failure; * Acute liver cell failure; * Use of drugs from "metabolic agents" pharmacotherapeutic group at the time of inclusion in the study * Life expectancy of 6 months or less or presence of incurable diseases in decompensation stage
Where it's running
-
Brain Institute Clinic
Yekaterinburg, Sverdlovsk Oblast, Russia Recruiting
Study contacts
- Study coordinator: Andrey Belkin, MD
- Email: belkin@neuro-ural.ru
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Remote ischemic conditioning for post-stroke insomnia
A 136-person, randomized study will test whether a non-invasive arm-cuff procedure done twice daily for 90 days can improve sleep after a first ischemic stroke in adults 18–80.
-
Ear-based nerve stimulation to help sleep after a stroke
A device that delivers vagal nerve stimulation through the ear is tested to see if it helps stroke patients in rehab sleep better.
-
Theta Burst Stimulation to Help Stroke Recovery (Upper and Lower Limbs)
This trial tests whether applying theta burst stimulation to the motor cortex, in combination with standard rehabilitation, helps people over 45 who recently had a first ischemic stroke recover arm and leg movement.
-
Preventing another ischemic stroke with a smart bracelet and app
This study tests whether a digital prevention program using a wearable and a mobile app can help people who recently had an ischemic stroke reduce the chance of another stroke and improve risk-factor control.
-
Photon-counting CT to check intracranial stents
This study tests whether ultra-high-resolution photon-counting CT can reliably visualize intracranial stents and detect in-stent restenosis during follow-up of patients with prior stents.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.